Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.72 |
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | KDR | P35968 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.53 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.53 |
| ▸ | BRAF | P15056 | 2/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.53 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18038020 | 0.86 | KMT2A (0.62) | KMT2AMEN1MAPTHTTRAB9A | |
| SCHEMBL18037971 | 0.84 | KMT2A (1.00) | KMT2AMEN1MAPTHTTRAB9A | |
| SCHEMBL18038044 | 0.84 | KMT2A (0.81) | KMT2ARAB9AALDH1A1MAPK1NPC1 | |
| SCHEMBL18038049 | 0.83 | KMT2A (0.67) | KMT2AMEN1MAPTRAB9AKDR | |
| SCHEMBL18038045 | 0.82 | KMT2A (0.78) | KMT2AMEN1MAPTHTTRAB9A | |
| SCHEMBL30481107 | 0.81 | KDR (0.67) | KMT2AALDH1A1KDR | |
| SCHEMBL18053822 | 0.81 | KDR (0.67) | KMT2AALDH1A1KDR | |
| SCHEMBL30481106 | 0.81 | KDR (0.67) | KMT2AALDH1A1KDR | |
| SCHEMBL19900444 | 0.81 | KMT2A (0.75) | KMT2AMEN1LMNAMAPK14GRIK1 | |
| SCHEMBL30151336 | 0.81 | KMT2A (0.75) | KMT2AMEN1LMNAMAPK14GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3261631-B1 | INHIBITION OF OLIG2 ACTIVITY | CURTANA PHARMACEUTICALS INC (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20230271926-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2023-08-31 | — | — | US | disclosed |
| US-20230271926-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2023-08-31 | — | — | US | disclosed |
| US-20230271926-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2023-08-31 | — | — | US | disclosed |
| US-11691951-B2 | Inhibition of Olig2 activity | Curtana Pharmaceuticals, Inc. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11691951-B2 | Inhibition of Olig2 activity | Curtana Pharmaceuticals, Inc. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11691951-B2 | Inhibition of Olig2 activity | Curtana Pharmaceuticals, Inc. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20210347739-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2021-11-11 | — | — | US | disclosed |
| US-20210347739-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2021-11-11 | — | — | US | disclosed |
| US-20210114991-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2021-04-22 | — | — | US | disclosed |
| US-20210114991-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2021-04-22 | — | — | US | disclosed |
| US-20180244631-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2018-08-30 | — | — | US | disclosed |
| EP-3261631-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. (US) | 2018-01-03 | — | — | EP | disclosed |
| WO-2016138479-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. (US) | 2016-09-01 | — | — | WO | disclosed |
| WO-2016138479-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. (US) | 2016-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210114991-A1 | INHIBITION OF OLIG2 ACTIVITY | GLI2, ING2, GMFG | KMT2A 501/4885MEN1 2974/4885MAPT 1722/4885 |
| US-20180244631-A1 | INHIBITION OF OLIG2 ACTIVITY | GLI2, ING2, GMFG | KMT2A 501/4885MEN1 2974/4885MAPT 1722/4885 |
| US-11691951-B2 | Inhibition of Olig2 activity | GLI2, ING2, GMFG | KMT2A 501/4885MEN1 2974/4885MAPT 1722/4885 |
| US-20210347739-A1 | INHIBITION OF OLIG2 ACTIVITY | GLI2, ING2, GMFG | KMT2A 501/4885MEN1 2974/4885MAPT 1722/4885 |
| US-20230271926-A1 | INHIBITION OF OLIG2 ACTIVITY | GLI2, ING2, GMFG | KMT2A 501/4885MEN1 2974/4885MAPT 1722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.